Loading
Using a tumour's gene expression or a patient's inherited variants to predict who needs more dose, who needs less, and who is at risk of severe side effects.
Two strands share the name. Tumour radiogenomics builds signatures such as the radiosensitivity index and the genomic-adjusted radiation dose that estimate how sensitive a tumour is and propose a personalised dose; prospective trials are beginning to test dose adjustment on these scores. Patient radiogenomics looks for inherited variants that predict normal-tissue toxicity, through consortia such as REQUITE and the Radiogenomics Consortium; effect sizes have been modest so far. Both aim to replace one-dose-fits-all prescriptions with dose tailored to biology.
Gene expression or germline variants correlate with tumour or normal-tissue radiosensitivity and can guide dose prescription.
Query for this technology: (TITLE:"Radiogenomics: predicting radiation sensitivity from genes" OR ABSTRACT:"Radiogenomics: predicting radiation sensitivity from genes") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Radiogenomics: predicting radiation sensitivity from genes, not a curated reading list.
Shares Alpha/beta ratio, IMRT / IGRT (modern external beam) and the tag radiation-wave1.
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave1.
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave1.
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave1.
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave1.
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave1.
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave1.
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave1.